scholarly journals Implementation Of A Data Mining Model Within A Monitoring Web-Based Tool To Assess HER2 Breast Cancer Status Using The Her-France Real World Database

2017 ◽  
Vol 20 (9) ◽  
pp. A748
Author(s):  
T Vauléon ◽  
D Pau ◽  
J Dupin ◽  
D Magrez ◽  
J Martin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Data Mining ◽  
Real World ◽  
Web Based ◽  
Her2 Breast Cancer ◽  
Mining Model

Factors influencing HER2 positivity in breast cancer according to statistical modeling and data mining techniques based on a real-world national database: HER-France.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e12086-e12086
Author(s):  
Marie-Pierre Chenard ◽  
Eric Anger ◽  
Marie-Helene Bizollon ◽  
Jerome Chetritt ◽  
Francesco Bruno Cutuli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Data Mining ◽  
Statistical Modeling ◽  
Real World ◽  
National Database ◽  
Data Mining Techniques ◽  
Factors Influencing ◽  
Her2 Positivity

Safety of a trastuzumab biosimilar, used under routine clinical practice conditions in adult HER2+ breast cancer patients in Morocco.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e13024-e13024
Author(s):  
Hassan Errihani ◽  
Narjiss Berrada ◽  
Mouna Khouchani ◽  
Abdelkader Acharki ◽  
Kamal Lahbabi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Adverse Events ◽  
Early Breast Cancer ◽  
Real World ◽  
Safety Profile ◽  
Safety Data ◽  
Routine Clinical Practice ◽  
Her2 Breast Cancer

e13024 Background: Hertraz, the first trastuzumab biosimilar was approved in Morocco in 2017. Real world data on trastuzumab biosimilars are very limited or not available. HERLife is a prospective, non-interventional phase IV study program that investigated the experience of using Hertraz, a biosimilar for trastuzumab (Herceptin), under routine clinical practice conditions in Morocco. The primary aim of this study was to confirm the acceptable safety and tolerability of Hertraz. Methods: Ninety-nine patients with HER2-positive breast cancer treated with Hertraz were enrolled from 8 public and private sector hospitals and followed up for 12 months as part of this non-interventional study. Cardiac events (LVEF) and other unexpected or serious adverse events were monitored. The study arms consisted of patients with early breast cancer (Arm 1, n=70) and metastatic breast cancer (Arm 2, n=29) whose median age was 53 years in both groups. Results: Switching from Herceptin to Hertraz was observed in 45% of 29 MBC patients and 27% of 70 EBC patients. Switching was done at a median of 4th cycle. Pertuzumab was used in combination with Hertraz in 69% and 19% of patients in the metastatic and neoadjuvant settings, respectively. Two patients had a decline in LVEF. One patient treated with Hertraz alone and one patient treated with Hertraz and pertuzumab developed a decrease in LVEF requiring a three-week treatment discontinuation of Hertraz. Treatment of Hertraz was continued after 1 skipped cycle without occurrence of new side effects. No other trastuzumab related adverse events was observed. Four patients in the metastatic group and 2 patients in the early breast cancer arm had a relapse in the 12 months of clinical follow-up. Conclusions: The management of HER2+ breast cancer in Morocco follows the international recommendations. This is the first real world safety data of Hertraz from Morocco. The 12-month follow-up treatment with Hertraz showed an acceptable cardiac safety profile. In cases where there was a switch from Herceptin to Hertraz or Hertraz combined with pertuzumab, the safety profile was similar to that previously reported in other studies.

scholarly journals Pyrotinib in the treatment of women with advanced HER2 positive breast cancer: A multicenter, prospective, real-world study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e13012-e13012
Author(s):  
Jifeng Feng ◽  
Lili Zhang ◽  
Xiaohong Wu ◽  
Jun Zhou ◽  
Mingzhen Zhu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Real World ◽  
Kinase Inhibitor ◽  
Objective Response ◽  
Progression Free Survival ◽  
Efficacy Evaluation ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Her2 Breast Cancer ◽  
Positive Breast Cancer

e13012 Background: Pyrotinib is a newly-developed irreversible pan-ErbB receptor tyrosine kinase inhibitor. The efficacy of pyrotinib in patients with different baseline characteristics in the actual clinical practice has been rarely reported. This study analyzed the efficacy and safety of pyrotinib in the real world. Methods: Patients with histologically confirmed advanced HER2 positive breast cancer were included in the analyses. All patients received pyrotinib-based therapy were given pyrotinib once a day in a 21-day cycle. The primary endpoint was progression-free survival (PFS). Secondary endpoints included adverse events (AE), objective response rate (ORR), disease control rate (DCR), and overall survival (OS). Results: A total of 132 patients (median age: 52 years [29-78]) were enrolled from February 2019 to March 2020. 94(71.21%) patients had visceral metastatic lesions and 20 (15.15%) had brain metastases. HR+, HR-, or unknown HR status for primary tumor accounted for 56.82%, 42.42%, 0.76%, respectively. 115(87.12%) patients were previously administered with trastuzumab. 96(72.73%) patients received pyrotinib-based therapy as a second or further line of treatment. 94(71.21%) patients initiated pyrotinib treatment at 400 mg. Treatment regimens were pyrotinib plus capecitabine (55.30%), pyrotinib combined with trastuzumab (18.18%), and pyrotinib monotherapy (8.33%), pyrotinib combined with endocrine therapy, radiotherapy or antiangiogenic drugs (3.79%). A total of 132 patients were included in PFS analysis. mPFS was 12.0 months (95%CI 8.1-18.8). mPFS for patients without primary trastuzumab-resistant breast cancer was 14.1 months (95%CI 8.7-23.3). Patients receiving pyrotinib-based therapy as their ≥3 lines treatment had lower mPFS than those receiving pyrotinib-based therapy as their < 3 lines treatment (8.8 vs. 15.1 months, P= 0.119). mPFS in patients receiving regimen with and without capecitabine were 15.1 months and 8.4 months, respectively ( P= 0.081). As of data cutoff, mOS has not yet been reached. Among the 65 patients available for efficacy evaluation, 1 (1.54%) patient achieved complete response (CR), 24 (36.92%) patients had partial response (PR), 30 (46.15%) patients achieved stable disease (SD), and 10 (15.38%) patients had progression disease (PD), resulting in an ORR of 38.46% and DCR of 84.62%. The most common AE was diarrhea (84.17%), but only 5 (4.17%) patients were reported grade ≥ 3 diarrhea which could be well controlled. Other AEs with an incidence higher than 20.00% were anemia (36.67%), leukopenia (25.83%), vomiting (25.00%), neutropenia (22.50%). No treatment-related death occurred. Conclusions: Pyrotinib demonstrated an encouraging efficacy and manageable safety in patients with advanced HER2+ breast cancer. More data would be analyzed and reported in the future. Clinical trial information: ChiCTR1900021819.

scholarly journals 82P A multinational study of real-world treatment patterns among patients with early stage HR+/HER2- breast cancer (BC)

2020 ◽  
Vol 31 ◽  
pp. S42-S43
Author(s):  
C. Criscitiello ◽  
D. Spurden ◽  
A. Rider ◽  
R. Williams ◽  
M. Corsaro ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Real World ◽  
Early Stage ◽  
Treatment Patterns ◽  
Multinational Study ◽  
Her2 Breast Cancer

scholarly journals Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran

PLoS ONE ◽  
2018 ◽  
Vol 13 (10) ◽  
pp. e0205079 ◽  
Author(s):  
Amir Ansaripour ◽  
Kazem Zendehdel ◽  
Niki Tadayon ◽  
Fatemeh Sadeghi ◽  
Carin A. Uyl-de Groot ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Data Mining ◽  
Real World ◽  
Her2 Positive ◽  
Cost Analyses ◽  
Her2 Positive Breast Cancer ◽  
Use Of Data ◽  
Positive Breast Cancer

scholarly journals Use of Data-Mining to Perform a Real World Cost Analysis of Her2-Positive Breast Cancer In Iran

2016 ◽  
Vol 19 (7) ◽  
pp. A355 ◽  
Author(s):  
A Ansaripour ◽  
K Zendehdel ◽  
N Tadayon ◽  
F Sadeghi ◽  
C Uyl-de Groot ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Data Mining ◽  
Cost Analysis ◽  
Real World ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Use Of Data ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document